Benzinga
Benzinga
Benzinga
jueves, septiembre 10

BridgeBio Pharma Inc

BBIONASDAQ
Trade with Public
Trade with Public
$72.50
-3.58-4.71%
al cierre: Sep 10, 5:00 PM EST
$73.00
0.500.69%
After hour: 5:02 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

BridgeBio Pharma Financials

BridgeBio Pharma (BBIO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.59) by 32.2 percent. This is a 17.89 percent increase over losses of $(0.95) per share
Benzinga Newsdesk

PRO
BridgeBio Pharma Q1 EPS $(0.84) Misses $(0.67) Estimate, Sales $194.515M Beat $177.937M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.67) by 25.37 percent. This is a 4.55 percent increase over losses of $(0.88) per share from
Benzinga Newsdesk

BridgeBio Pharma Earnings Review: Q4 Summary

Benzinga Insights

PRO
BridgeBio Pharma Q4 EPS $(1.00) Misses $(0.66) Estimate, Sales $154.178M Beat $146.844M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.66) by 52.67 percent. This is a 28.57 percent increase over losses of $(1.40) per share
Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights

Insights Ahead: BridgeBio Pharma's Quarterly Earnings

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved